This is an excellent question and one we are seeing more and more in clinic these days now that the FDA has approved nivolumab for adjuvant therapy for patients with locally advanced urothelial carcinoma at high risk of recurrence after radical resection. This is based on data from CheckMate 274 whi...

CheckMate 274 reported that in patients with high-risk muscle-invasive urothelial carcinoma who had undergone radical surgery, disease-free survival was longer with adjuvant nivolumab (vs placebo) in the intention-to-treat population (median 20.8 vs. 10.8 months, HR 0.70, P<0.001) and among patie...

For a patient who proceeds to radical cystectomy first with high risk MIBC (pT3, pT4a, or pN+), based on the limitations of the CM274 data and the specific eligibility criteria that were used in the study (i.e., not eligible for or declined adjuvant cisplatin-based combination chemotherapy), I ...

At the present moment, overall survival data is not yet available regarding adjuvant Nivolumab post-cystectomy. Therefore, at present, if patients meet the criteria to safely receive Cisplatin, I prioritize adjuvant Cisplatin-based chemotherapy in my treatment discussions with patients. I do, howeve...